secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0000950170-21-004845
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Pharma Q4 net loss $24.6M; FY net loss $79M; terminates HBV asset, plans COVID protease inhibitor
--------------------------------------------------------------------------------

- Q4 revenue $23.6M (flat YoY); net loss $24.6M ($1.22 loss per diluted share) vs $29.3M loss a year ago.
- FY revenue $97.1M (down 21% from $122.5M); net loss $79M ($3.92 loss per diluted share) vs $36.2M loss.
- Terminated EDP-721 (HBV RNA destabilizer) due to adverse safety signals; positive Phase 1b data for EDP-514 HBV core inhibitor.
- Plans to advance EDP-235 oral protease inhibitor for COVID-19 into Phase 1 in early 2022.
- Discontinued internal NASH FXR agonist development; will pursue out-licensing; FY2022 guidance: R&D $150-170M, G&A $35-41M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017021004845/0000950170-21-004845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017021004845/enta-20211122.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer